iTeos Therapeutics, Inc.: restructuring charge — iTeos Therapeutics to wind down operations after terminating belrestotug program and GSK collaboration

iTeos Therapeutics, Inc.

Will wind down operations; expects severance charges of $21.8M-$24.7M and other program wind-down costs of $11.1M.
Exploring potential asset sales including EOS-984, EOS-215, and preclinical obesity program targeting ENT1.
Wind down substantially complete in Q3 2025; clinical development programs to wind down thereafter.
Amended employment agreements for CEO, COO, CMO with enhanced severance if terminated during change in control (excluding dissolution).

Key facts

Extracted from this filing and checked against the source text.

Restructurings & Charges SEC 8-K Item 2.05/2.06 confidence 0.9

iTeos Therapeutics, Inc. announced a restructuring with charges of $21.8 million to $24.7 million affecting Company-wide (clinical and operational activities).

Type: restructuring
Charge: $21.8 million to $24.7 million
Affected area: Company-wide (clinical and operational activities)

Exact text from the filing

The Company expects to incur charges in connection with the wind down consisting of (i) severance and other termination costs related to employees who would be terminated of approximately $21.8 million to $24.7 million

View on SEC.gov

Browse all restructurings & charges →

Source: SEC EDGAR

accession 0000950170-25-078084

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.